NL-OMON24912RecruitingPhase 3
Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018
German Pediatric Oncology Group (GPOH)0 sites10 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- Enrollment
- 10
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 0 to 11 (—)
Inclusion Criteria
- •- Myeloïde leukemie (ML) of Myelodysplastisch Syndroom (MDS), volgens de WHO.
- •- Trisomie 21: syndroom van Down of mosaic.
Exclusion Criteria
- •- Kinderen met ‘Transient Abnormal Myelopoiesis (TAM), volgens de WHO. |
Investigators
Similar Trials
Recruiting
Phase 3
Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018NL-OMON55026German Pediatric Oncology Group (GPOH) gGmbH10
Active, not recruiting
Phase 1
Clinical Trial for the Treatment of Myeloid Leukemia in Children with Down SyndromeEUCTR2018-002988-25-DEGesellschaft für Pädiatrische Onkologie & Hämatologie (GPOH gGmbH)150
Active, not recruiting
Phase 1
Clinical Trial for the Treatment of Myeloid Leukemia in Children with Down SyndromeMyeloid Leukemia in Children with Down SyndromeEUCTR2018-002988-25-NLGesellschaft für Pädiatrische Onkologie & Hämatologie (GPOH gGmbH)150
Active, not recruiting
Phase 1
Clinical Trial for the Treatment of Myeloid Leukemia in Children with Down SyndromeEUCTR2018-002988-25-ATGesellschaft für Pädiatrische Onkologie & Hämatologie (GPOH gGmbH)150
Active, not recruiting
Phase 1
Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018Myeloid Leukemia in Children with Down SyndromeCTIS2022-501457-37-00GPOH gGmbH185